Julien C. Vantourout; Andrew M. Mason; Josephine Yuen; Graham L. Simpson; Ghotas Evindar; Letian Kuai; Michael Hobbs; Emma Edgar; Saul Needle; Xiaopeng Bai; Steve Wilson; Paul Scott-Stevens; William Traylen; Kim Lambert; Neil Young; Shenaz Bunally; Scott G. Summerfield; Richard Snell; Rakesh Lad; Eric Shi; Steven Skinner; Lisa Shewchuk; Allan J.B. Watson; Chun-wa Chung; Sandeep Pal; Dennis A. Holt; Lara S. Kallander; Joanne Prendergast; Katrina Rivera; David G. Washburn; Mark R. Harpel; Christopher Arico-Muendel; Albert Isidro-Llobet
Bioconjugate Chem., 2021, 32, 2, 279-289
https://doi.org/10.1021/acs.bioconjchem.0c00662

Abstract

Reducing the required frequence of drug dosing can improve the adherence of patients to chronic treatments. Hence, drugs with longer in vivo half-lives are highly desirable. One of the most promising approaches to extend the in vivo half-life of drugs is conjugation to human serum albumin (HSA). In this work, we describe the use of AlbuBinder 1, a small-molecule noncovalent HSA binder, to extend the in vivo half-life and pharmacology of small-molecule BMP1/TLL inhibitors in humanized mice (HSA KI/KI). A series of conjugates of AlbuBinder 1 with BMP1/TLL inhibitors were prepared. In particular, conjugate c showed good solubility and a half-life extension of >20-fold versus the parent molecule in the HSA KI/KI mice, reaching half-lives of >48 h with maintained maximal inhibition of plasma BMP1/TLL. The same conjugate showed a half-life of only 3 h in the wild-type mice, suggesting that the half-life extension was principally due to specific interactions with HSA. It is envisioned that conjugation to AlbuBinder 1 should be applicable to a wide range of small molecule or peptide drugs with short half-lives. In this context, AlbuBinders represent a viable alternative to existing half-life extension technologies.